{"component": "clause", "props": {"groups": [{"snippet": "Distributor hereby commits to Supplier to achieve, at a minimum, the sales targets set forth on Exhibit C hereto during the Term (\u201cSales Minimum\u201d), and the Total Value of orders for each year listed therein (the \u201cOrder Value\u201d). If Distributor fails to achieve the Sales Minimum and/or the Order Value in any given period specified in Exhibit C hereto, Supplier may, at its own discretion either: (i) terminate this Agreement in accordance with Section 9.1 below, or (ii) revoke the exclusive appointment granted to the Distributor under Section 1.3 and appoint Distributor as a non-exclusive Distributor in the Territory. Supplier shall notify Distributor if\u2019 such appointment is made. Said appointment shall not derogate from the terms of this Agreement and all other terms of this Agreement shall remain in effect Mutatis Mutandis.", "size": 8, "snippet_links": [{"key": "sales-targets", "type": "definition", "offset": [69, 82]}, {"key": "exhibit-c", "type": "definition", "offset": [96, 105]}, {"key": "during-the-term", "type": "clause", "offset": [113, 128]}, {"key": "total-value", "type": "definition", "offset": [156, 167]}, {"key": "of-orders", "type": "clause", "offset": [168, 177]}, {"key": "each-year", "type": "definition", "offset": [182, 191]}, {"key": "order-value", "type": "definition", "offset": [213, 224]}, {"key": "terminate-this-agreement", "type": "clause", "offset": [400, 424]}, {"key": "in-accordance-with", "type": "definition", "offset": [425, 443]}, {"key": "section-91", "type": "definition", "offset": [444, 455]}, {"key": "exclusive-appointment", "type": "clause", "offset": [482, 503]}, {"key": "granted-to", "type": "definition", "offset": [504, 514]}, {"key": "the-distributor", "type": "definition", "offset": [515, 530]}, {"key": "section-13", "type": "clause", "offset": [537, 548]}, {"key": "a-non", "type": "clause", "offset": [576, 581]}, {"key": "exclusive-distributor", "type": "definition", "offset": [582, 603]}, {"key": "in-the-territory", "type": "clause", "offset": [604, 620]}, {"key": "supplier-shall", "type": "clause", "offset": [622, 636]}, {"key": "the-terms", "type": "definition", "offset": [727, 736]}, {"key": "other-terms-of-this-agreement", "type": "clause", "offset": [763, 792]}, {"key": "in-effect", "type": "definition", "offset": [806, 815]}], "samples": [{"hash": "bot5pu1DMGZ", "uri": "/contracts/bot5pu1DMGZ#sales-minimums", "label": "Exclusive Distribution Agreement (InspireMD, Inc.)", "score": 20.7768651608, "published": true}, {"hash": "54XV75s9U7E", "uri": "/contracts/54XV75s9U7E#sales-minimums", "label": "Exclusive Distribution Agreement (InspireMD, Inc.)", "score": 20.6481861739, "published": true}], "hash": "8be9a0cd26cc62e7f85746d242c45b40", "id": 1}, {"snippet": "PreMD hereby waives any rights which it may have as a result of \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 not having cumulative Net Sales of Products pursuant to section 17.3(a) for the 2004, 2005 and 2006 Calendar Years (it being understood that the obligations of \u2587\u2587\u2587\u2587\u2587\u2587 pursuant to section 17.3(a) shall arise only in respect of the 2007 and subsequent Calendar Years), subject to the ability of \u2587\u2587\u2587\u2587\u2587\u2587 to ***** provided for in section 17.3 of the Agreement.", "size": 2, "snippet_links": [{"key": "hereby-waives", "type": "clause", "offset": [6, 19]}, {"key": "net-sales-of-products", "type": "definition", "offset": [95, 116]}, {"key": "section-173", "type": "clause", "offset": [129, 141]}, {"key": "calendar-years", "type": "clause", "offset": [173, 187]}, {"key": "obligations-of", "type": "clause", "offset": [218, 232]}, {"key": "in-respect-of", "type": "clause", "offset": [285, 298]}, {"key": "subject-to-the", "type": "definition", "offset": [340, 354]}, {"key": "the-agreement", "type": "clause", "offset": [414, 427]}], "samples": [{"hash": "lGnCVpiyWym", "uri": "/contracts/lGnCVpiyWym#sales-minimums", "label": "License, Development and Supply Agreement (PreMD Inc.)", "score": 17.0, "published": true}], "hash": "a90b922eb6b9a4e8574d035bf811d900", "id": 2}, {"snippet": "a. The Country may be removed from the Territory if Sales in the Country (in United States Dollars \u201cUSD\u201d) are below the following minimum amounts (Year 1 commences on the date of the first sale of Products in the Country):\n1. Year 1 $1.0 million 2. Year 2 $1.8 million 3. Year 3 $3.0 million 4. Year 4 $4.5 million 5. Year 5 $6.5 million", "size": 2, "snippet_links": [{"key": "the-country", "type": "definition", "offset": [3, 14]}, {"key": "the-territory", "type": "clause", "offset": [35, 48]}, {"key": "united-states-dollars", "type": "definition", "offset": [77, 98]}, {"key": "minimum-amounts", "type": "clause", "offset": [130, 145]}, {"key": "year-1", "type": "clause", "offset": [147, 153]}, {"key": "date-of", "type": "clause", "offset": [171, 178]}, {"key": "sale-of-products", "type": "definition", "offset": [189, 205]}, {"key": "year-2", "type": "definition", "offset": [249, 255]}, {"key": "year-3", "type": "definition", "offset": [272, 278]}, {"key": "year-4", "type": "definition", "offset": [295, 301]}, {"key": "year-5", "type": "definition", "offset": [318, 324]}], "samples": [{"hash": "jSoP3WWucTt", "uri": "/contracts/jSoP3WWucTt#sales-minimums", "label": "Sales and Marketing Agreement (RBC Life Sciences, Inc.)", "score": 23.2327173169, "published": true}], "hash": "20868d380e26e020b8b8048c45cc85d5", "id": 3}, {"snippet": "Based on the Marketing Plan and Analysis and the Production Plan, the parties shall agree on minimum sales amounts for each Product in the geographical areas of the world. Such sales minimums may provide for an initial introduction period with increasing amounts to be met during subsequent time periods. The minimum sales amounts shall be set forth on Exhibit \"D\" attached hereto and incorporated herein by this reference which shall be attached to this Agreement and become a part thereof. SSRI's exclusive rights to market and sell the Products shall remain in effect so long as the minimums set forth on Exhibit \"D\" for the identified geographical markets are met or exceeded. To the extent that such sales minimums are not met for a particular geographic market, LarsonoDavis shall have the right to terminate SSRI's exclusive rights to such geographical market by providing 30 days written notice to SSRI of its failure to meet the minimum sales requirements. Subsequent to the termination SSRI's exclusive rights in any geographical market, \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 shall have the right to directly, or indirectly through sales representatives or distributors, sell Products into such geographical market; provided that, such failure was not the result of \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 not delivering Products or meeting production schedules.", "size": 1, "snippet_links": [{"key": "based-on", "type": "clause", "offset": [0, 8]}, {"key": "the-marketing-plan", "type": "clause", "offset": [9, 27]}, {"key": "production-plan", "type": "definition", "offset": [49, 64]}, {"key": "the-parties-shall", "type": "clause", "offset": [66, 83]}, {"key": "geographical-areas", "type": "definition", "offset": [139, 157]}, {"key": "the-world", "type": "definition", "offset": [161, 170]}, {"key": "provide-for", "type": "clause", "offset": [196, 207]}, {"key": "introduction-period", "type": "clause", "offset": [219, 238]}, {"key": "amounts-to-be", "type": "clause", "offset": [255, 268]}, {"key": "time-periods", "type": "definition", "offset": [291, 303]}, {"key": "to-this-agreement", "type": "clause", "offset": [447, 464]}, {"key": "exclusive-rights", "type": "definition", "offset": [499, 515]}, {"key": "the-products", "type": "clause", "offset": [535, 547]}, {"key": "in-effect", "type": "definition", "offset": [561, 570]}, {"key": "to-the-extent", "type": "clause", "offset": [681, 694]}, {"key": "not-met", "type": "definition", "offset": [724, 731]}, {"key": "geographic-market", "type": "clause", "offset": [749, 766]}, {"key": "right-to-terminate", "type": "clause", "offset": [796, 814]}, {"key": "notice-to", "type": "definition", "offset": [896, 905]}, {"key": "failure-to-meet", "type": "clause", "offset": [918, 933]}, {"key": "minimum-sales-requirements", "type": "clause", "offset": [938, 964]}, {"key": "the-termination", "type": "clause", "offset": [980, 995]}, {"key": "sales-representatives", "type": "clause", "offset": [1117, 1138]}, {"key": "provided-that", "type": "clause", "offset": [1201, 1214]}, {"key": "production-schedules", "type": "clause", "offset": [1299, 1319]}], "samples": [{"hash": "clnObGD3a9a", "uri": "/contracts/clnObGD3a9a#sales-minimums", "label": "Product Development and Marketing Agreement (Larson Davis Inc)", "score": 18.0, "published": true}], "hash": "7feebb6f9289a04c14618a9a65c13b34", "id": 4}, {"snippet": "Subject to Section 2.17, AMI will exercise commercially reasonable efforts to achieve the Sales Minimum specified below for the specified period:\n(a) For Calendar Year 2009, either\n(i) if AMI or its Affiliates Commercialize a Cannibalizing Product in 2009, a Sales Minimum of [*] U.S. Dollars (US$[*]); or\n(ii) if AMI or its Affiliates do not Commercialize a Cannibalizing Product in 2009 there will be no Sales Minimum.\n(b) For Calendar Year 2010, either\n(i) if AMI or its Affiliates Commercialize a Cannibalizing Product in 2010, a Sales Minimum of [*] U.S. Dollars (US$[*]); or\n(ii) if AMI or its Affiliates do not Commercialize a Cannibalizing Product in 2010, there will be no Sales Minimum.\n(c) For Calendar Year 2011 and each subsequent Calendar Year during the Initial Term, the Sales Minimum will be the greater of [*] U.S. Dollars (US$[*]) or [*] percent ([*]%) of AMI\u2019s long-range plan forecast for Celera Products for such Calendar Year, as determined six (6) months prior to the start of such Calendar Year; provided, the Sales Minimum for each Calendar Year after the Initial Term, if any, will be adjusted pro rata based upon AMI\u2019s purchases for distribution in the EEA pursuant to Section 3.1.\n(d) By August 31, 2012, AMI will provide to Celera a non-binding forecast for Celera Products in the Territory for the first Renewal Term for the purpose of agreement by the Parties on the Sales Minimums for such first Renewal Term, if any.\n(e) By August 31, 2014, AMI will provide to Celera a non-binding forecast for Celera Products in the Territory for the second Renewal Term for the purpose of agreement by the Parties on the Sales Minimums for such second Renewal Term, if any.", "size": 1, "snippet_links": [{"key": "section-217", "type": "definition", "offset": [11, 23]}, {"key": "commercially-reasonable-efforts", "type": "definition", "offset": [43, 74]}, {"key": "the-sales", "type": "definition", "offset": [86, 95]}, {"key": "specified-period", "type": "definition", "offset": [128, 144]}, {"key": "no-sales", "type": "clause", "offset": [403, 411]}, {"key": "calendar-year-2010", "type": "clause", "offset": [429, 447]}, {"key": "during-the-initial-term", "type": "clause", "offset": [758, 781]}, {"key": "prior-to-the", "type": "clause", "offset": [979, 991]}, {"key": "each-calendar-year", "type": "definition", "offset": [1053, 1071]}, {"key": "after-the-initial-term", "type": "clause", "offset": [1072, 1094]}, {"key": "pro-rata", "type": "clause", "offset": [1121, 1129]}, {"key": "for-distribution", "type": "clause", "offset": [1157, 1173]}, {"key": "section-31", "type": "clause", "offset": [1197, 1208]}, {"key": "by-august", "type": "clause", "offset": [1214, 1223]}, {"key": "will-provide", "type": "clause", "offset": [1238, 1250]}, {"key": "a-non", "type": "clause", "offset": [1261, 1266]}, {"key": "binding-forecast", "type": "clause", "offset": [1267, 1283]}, {"key": "in-the-territory", "type": "clause", "offset": [1304, 1320]}, {"key": "first-renewal-term", "type": "definition", "offset": [1329, 1347]}, {"key": "agreement-by-the-parties", "type": "clause", "offset": [1367, 1391]}, {"key": "second-renewal-term", "type": "definition", "offset": [1570, 1589]}], "samples": [{"hash": "g0GcHyeRUJ0", "uri": "/contracts/g0GcHyeRUJ0#sales-minimums", "label": "Distribution Agreement (Celera CORP)", "score": 21.0, "published": true}], "hash": "15ebfa74fa8513040d735fd7a7ff8338", "id": 5}, {"snippet": "Professional Product", "size": 1, "snippet_links": [], "samples": [{"hash": "xAjPweiQUO", "uri": "/contracts/xAjPweiQUO#sales-minimums", "label": "License, Development and Supply Agreement (PreMD Inc.)", "score": 17.0, "published": true}], "hash": "742022df00cc076e0f800b06de4cafd0", "id": 6}, {"snippet": "(a) In the event LabCorp fails to sell at least the number of Harmony Tests as set forth in Exhibit 5.3(a), as adjusted by Section 5.3(b) below (the \u201cSales Minimums\u201d) during the applicable calendar year of the Exclusive Period or any calendar quarter which falls within the calendar year in which the Exclusive Period expires, then ARIOSA shall notify LabCorp in writing and LabCorp [*]. In the event LabCorp does not [*], ARIOSA shall have the option to convert the Exclusive Period to the Non-Exclusive Period as provided in Section 6.1. For purposes of clarification, conversion of the Exclusive Period to the Non-Exclusive Period [*].\n(b) In the event of a Test Stoppage, then LabCorp\u2019s obligation to meet Sales Minimums [*] shall be [*] suspended and waived and the Exclusive Period extended until the Test Stoppage is over (i.e., the injunction is removed, the necessary regulatory or other governmental approval has been obtained, or ARIOSA recovers from the Force Majeure condition and is able to perform the Harmony Test again). Once the Test Stoppage is over, the Sales Minimums will re-commence at the rate in effect immediately prior to the suspension, the Sales Minimums schedule [*] shall be adjusted and prorated to account for the time of such suspension, and the Exclusive Period shall be extended for the amount of time of the suspension.\n(c) In the event LabCorp\u2019s actual sales of the Harmony Test are less than [*], then the Collaboration Committee shall discuss in good faith a possible adjustment to Sales Minimums to reflect what can realistically be achieved and/or ARIOSA may convert to a Non-Exclusive Period [*].", "size": 1, "snippet_links": [{"key": "to-sell", "type": "clause", "offset": [31, 38]}, {"key": "number-of", "type": "clause", "offset": [52, 61]}, {"key": "as-adjusted", "type": "definition", "offset": [108, 119]}, {"key": "applicable-calendar-year", "type": "definition", "offset": [178, 202]}, {"key": "exclusive-period", "type": "definition", "offset": [210, 226]}, {"key": "calendar-quarter", "type": "clause", "offset": [234, 250]}, {"key": "in-writing", "type": "clause", "offset": [360, 370]}, {"key": "option-to-convert", "type": "definition", "offset": [445, 462]}, {"key": "the-non", "type": "clause", "offset": [487, 494]}, {"key": "section-61", "type": "clause", "offset": [527, 538]}, {"key": "for-purposes-of-clarification", "type": "clause", "offset": [540, 569]}, {"key": "conversion-of", "type": "clause", "offset": [571, 584]}, {"key": "in-the-event-of-a", "type": "clause", "offset": [643, 660]}, {"key": "obligation-to-meet", "type": "clause", "offset": [691, 709]}, {"key": "other-governmental-approval", "type": "clause", "offset": [891, 918]}, {"key": "force-majeure-condition", "type": "clause", "offset": [966, 989]}, {"key": "able-to-perform", "type": "clause", "offset": [997, 1012]}, {"key": "the-sales", "type": "definition", "offset": [1070, 1079]}, {"key": "the-rate", "type": "definition", "offset": [1109, 1117]}, {"key": "in-effect", "type": "definition", "offset": [1118, 1127]}, {"key": "prior-to-the", "type": "clause", "offset": [1140, 1152]}, {"key": "account-for-the", "type": "clause", "offset": [1231, 1246]}, {"key": "time-of-the", "type": "clause", "offset": [1333, 1344]}, {"key": "actual-sales", "type": "definition", "offset": [1384, 1396]}, {"key": "committee-shall", "type": "definition", "offset": [1459, 1474]}, {"key": "in-good-faith", "type": "definition", "offset": [1483, 1496]}, {"key": "adjustment-to", "type": "clause", "offset": [1508, 1521]}, {"key": "a-non", "type": "clause", "offset": [1612, 1617]}], "samples": [{"hash": "a8HJrPeAUCF", "uri": "/contracts/a8HJrPeAUCF#sales-minimums", "label": "Collaboration Agreement (Ariosa Diagnostics, Inc.)", "score": 25.1587953457, "published": true}], "hash": "d3a9807dfbfdedc3a1e6b0cb54190f0d", "id": 7}, {"snippet": "(a) Solely in Morocco, Pfizer Overseas agrees that aggregate Net Sales in Morocco shall equal at least U.S.$71,429, U.S.$857,143 and U.S.$1,787,714, respectively, for each of the first three Agreement Years for Morocco. In the event Pfizer Overseas or its Affiliates does not achieve such sales minima during any of the first three Agreement Years, Pfizer Overseas shall pay to Export, within 60 days after the end of such Agreement Year, an amount calculated as follows: the difference between 14% of Net Sales for the Agreement Year in which the shortfall occurred and (i) U.S.$10,000 in Agreement Year One, (ii) U.S.$120,000 in Agreement Year Two, and (iii) U.S.$250,000 in Agreement Year Three.\n(b) For example, if Pfizer Overseas achieved Net Sales equal to U.S.$60,000 in Agreement Year One, Pfizer Overseas would owe Export an amount equal to $1,600 (i.e., $10,000 minus ($60,000 X 14%)).", "size": 1, "snippet_links": [{"key": "aggregate-net-sales", "type": "definition", "offset": [51, 70]}, {"key": "in-the-event", "type": "clause", "offset": [220, 232]}, {"key": "to-export", "type": "definition", "offset": [375, 384]}, {"key": "days-after", "type": "definition", "offset": [396, 406]}, {"key": "agreement-year", "type": "definition", "offset": [423, 437]}, {"key": "the-agreement", "type": "clause", "offset": [516, 529]}, {"key": "in-agreement", "type": "clause", "offset": [587, 599]}, {"key": "year-one", "type": "clause", "offset": [600, 608]}, {"key": "year-two", "type": "definition", "offset": [641, 649]}, {"key": "year-three", "type": "clause", "offset": [687, 697]}, {"key": "for-example", "type": "definition", "offset": [703, 714]}, {"key": "equal-to", "type": "definition", "offset": [754, 762]}], "samples": [{"hash": "5WlA8NaATG4", "uri": "/contracts/5WlA8NaATG4#sales-minimums", "label": "International License Agreement (Warner Lambert Co)", "score": 16.0, "published": true}], "hash": "a226b2738ad31943d4f67108837a6636", "id": 8}, {"snippet": "In order for the Distributor to maintain its exclusive rights to market and sell Diabetinol\u00ae in the Market, Distributor shall be required to meet the sales minimums (the \u201cSales Minimums\u201d as further defined in Exhibit D) within eighteen months from June 1, 2025 (the \u201cSales Minimum Period\u201d). If Distributor is unable to meet the Sales Minimums within Sales Minimum Period, Distributor shall have sixty (60) days to cure and remedy the shortfall. Failure to cure within 30 days will result in the Distributor losing its exclusive rights to market and sell Diabetinol\u00ae in the Market, but shall not otherwise affect any of the terms or conditions of this Agreement (an \u201cExclusivity Termination\u201d). Distributor may extend the cure period for an additional 12 months with a one-time payment of five million dollars ($5,000,000) to Supplier.", "size": 1, "snippet_links": [{"key": "the-distributor", "type": "definition", "offset": [13, 28]}, {"key": "to-maintain", "type": "clause", "offset": [29, 40]}, {"key": "exclusive-rights", "type": "definition", "offset": [45, 61]}, {"key": "the-market", "type": "definition", "offset": [96, 106]}, {"key": "the-sales", "type": "definition", "offset": [146, 155]}, {"key": "further-defined", "type": "clause", "offset": [190, 205]}, {"key": "exhibit-d", "type": "definition", "offset": [209, 218]}, {"key": "eighteen-months", "type": "clause", "offset": [227, 242]}, {"key": "minimum-period", "type": "definition", "offset": [273, 287]}, {"key": "failure-to-cure", "type": "definition", "offset": [445, 460]}, {"key": "the-terms", "type": "definition", "offset": [619, 628]}, {"key": "conditions-of-this-agreement", "type": "clause", "offset": [632, 660]}, {"key": "exclusivity-termination", "type": "clause", "offset": [666, 689]}, {"key": "cure-period", "type": "clause", "offset": [720, 731]}, {"key": "an-additional", "type": "clause", "offset": [736, 749]}, {"key": "payment-of", "type": "definition", "offset": [776, 786]}], "samples": [{"hash": "9Xk1C69LUtG", "uri": "/contracts/9Xk1C69LUtG#sales-minimums", "label": "Master Distribution Agreement (Mangoceuticals, Inc.)", "score": 34.227926078, "published": true}], "hash": "b362e27392018d782720ca15bf391b05", "id": 9}, {"snippet": "3.1 BioLife agrees to manage the Company to achieve the following sales minimums:\n(a) Within 12 months of execution \u2013 deployment of at least [**Confidential Treatment Requested**] units\n(b) Within 24 months of execution \u2013 deployment of at least [**Confidential Treatment Requested**] units\n3.2 These sales minimums shall be adjusted as appropriate to take into account any problems in performance by SAVSU of its obligations to the Company or other factors out of the control of BioLife. Failure to meet these sales minimums would constitute a material breach on the part of BioLife with regard to which the Company would have the right to terminate under Section 11.2(a), and provided further that BioLife\u2019s obligations hereunder shall not exceed its commitment to provide capital contributions to the Company under the LLC Agreement.", "size": 1, "snippet_links": [{"key": "agrees-to", "type": "clause", "offset": [12, 21]}, {"key": "confidential-treatment-requested", "type": "definition", "offset": [144, 176]}, {"key": "take-into-account", "type": "definition", "offset": [351, 368]}, {"key": "performance-by", "type": "definition", "offset": [385, 399]}, {"key": "obligations-to-the-company", "type": "clause", "offset": [413, 439]}, {"key": "other-factors", "type": "clause", "offset": [443, 456]}, {"key": "control-of", "type": "definition", "offset": [468, 478]}, {"key": "failure-to-meet", "type": "clause", "offset": [488, 503]}, {"key": "material-breach", "type": "clause", "offset": [544, 559]}, {"key": "with-regard-to", "type": "clause", "offset": [583, 597]}, {"key": "right-to-terminate", "type": "clause", "offset": [631, 649]}, {"key": "to-provide", "type": "definition", "offset": [763, 773]}, {"key": "capital-contributions-to-the-company", "type": "clause", "offset": [774, 810]}, {"key": "llc-agreement", "type": "definition", "offset": [821, 834]}], "samples": [{"hash": "62O188uvkKy", "uri": "/contracts/62O188uvkKy#sales-minimums", "label": "Services Agreement (Biolife Solutions Inc)", "score": 25.8459958932, "published": true}], "hash": "245f0ad90033511ff13d368298334ecd", "id": 10}], "next_curs": "ClcSUWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjMLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhdzYWxlcy1taW5pbXVtcyMwMDAwMDAwYQyiAQJlbhgAIAA=", "clause": {"title": "Sales Minimums", "size": 23, "children": [], "parents": [["representations-undertakings-appointment-and-responsibilities-of-distributor", "Representations Undertakings Appointment and Responsibilities of Distributor"], ["payment-royalties-and-sales-minimums", "Payment, Royalties and Sales Minimums"], ["description-of-operations", "Description of Operations"], ["sales-and-marketing-services", "Sales and Marketing Services"], ["definitions", "DEFINITIONS"]], "id": "sales-minimums", "related": [["sales-milestones", "Sales Milestones", "Sales Milestones"], ["sales-milestone-payments", "Sales Milestone Payments", "Sales Milestone Payments"], ["adjustment-of-minimum-quarterly-distribution-and-target-distribution-levels", "Adjustment of Minimum Quarterly Distribution and Target Distribution Levels", "Adjustment of Minimum Quarterly Distribution and Target Distribution Levels"], ["minimum-annual-royalties", "Minimum Annual Royalties", "Minimum Annual Royalties"], ["minimum-order-quantity", "MINIMUM ORDER QUANTITY", "MINIMUM ORDER QUANTITY"]], "related_snippets": [], "updated": "2025-07-07T12:37:53+00:00", "also_ask": ["What negotiation levers exist for adjusting sales minimums to favor our position?", "Which specific performance metrics must be clearly defined to avoid ambiguity in sales minimums?", "What are the most common legal pitfalls or unenforceable provisions in sales minimum clauses?", "How do sales minimum requirements in this agreement compare to industry standards or competitor contracts?", "What evidence is typically required in court to enforce or challenge a sales minimums clause?"], "drafting_tip": "Specify clear sales targets to set expectations, define measurement periods to ensure accountability, and state consequences for non-compliance to promote enforceability.", "explanation": "The Sales Minimums clause sets a required baseline level of sales that a party, typically a distributor or licensee, must achieve within a specified period. This clause often details the minimum quantity or value of products or services that must be sold, and may outline consequences if these targets are not met, such as loss of exclusivity or termination of the agreement. Its core function is to ensure that the party responsible for sales maintains a satisfactory level of performance, thereby protecting the interests of the supplier or licensor and incentivizing active promotion and distribution."}, "json": true, "cursor": ""}}